Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Drug Discovery
- Multiple Sclerosis
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 273266
The Third Party hereby assigns to Buyer all of The Third Partyâ€™s rights under or pursuant to the License Agreement relating to Products and Improvements in the Territory.
Zanaflex Capsules and Zanaflex tablets contain tizanidine hydrochloride, or tizanidine, one of the two leading treatments currently used for the management of spasticity.
This medication is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury).
Licensee is a commercial-stage biopharmaceutical company which markets Zanaflex Capsules. Zanaflex Capsules and Zanaflex tablets, are FDA-approved for the management of spasticity, a symptom of conditions such as MS and SCI that is commonly characterized by stiffness and rigidity, restriction of movement and painful muscle spasms.
IPSCIO Record ID: 329689
– the Fampridine Product in the SCI Field for the SCI Term;
– the Fampridine Product in the MS Field for the MS Term; and
– without prejudice, the Product in the SCI Field, MS Field and/or Other Indication Field for the Other Indication Term, subject to any contractual obligations with respect to a formulation using Nanoformulation technology in the Other Indication Field.
Licensor grants a non-exclusive royalty free license in the Territory solely for use in connection with the sale of the Product, for the term of this Agreement to use any trademark which relates to the Licensor technology applicable to the Product.
Fampridine Product shall mean any finished pharmaceutical oral sustained release dosage form containing the Compound, which is in the scope of one or more Valid Claims within the Licensor Patent Rights in the country of sale, and/or incorporates Licensor Know-How in material part. The use of the pre-clinical, toxicological, pharmacokinetic, metabolic, formulation, methods, clinical protocols and data developed for and on behalf of Licensor, which is included in the Licensor Know-How shall constitute incorporation of the Licensor Know-How in material part.
Licensee patents used are Treating Diseases of the Anterior Horn Cells, and, the use of 4-Aminopyridine in the treatment of a neurological condition.
Licensors patents include Matrix Formulation of Potassium Chemical Blockers (Fampridine)
The field of use Indication shall mean any use or indication of Product for treatment of any condition, including spinal cord injury (SCI) and multiple sclerosis (MS).
MS Field shall mean use as an oral prescription medicine fort he treatment of MS in humans.
SCI Field shall mean use as an oral prescription medicine for the treatment of SCI in humans.
Other Indication Field shall mean use as a prescription medicine for the treatment of any condition in humans, excluding the SCI Field and the MS Field, but for the avoidance of doubt including the treatment of SCI and/or MS otherwise than orally.
IPSCIO Record ID: 291115
Licensor grants a non-exclusive license, with the right to grant sublicenses, in the territory for the term to use the Licensor trademark upon or in relation to the product.
The drug specificed for this agreement is Once-daily oral morphine capsules, containing SODASÂ® beads.
The trademark shall mean SODASÂ®.
The Product to be supplied to Licensee by Licensor shall be in the form of bulk two-piece hard gelatin capsules containing microparticulate SODASÂ® particles.
SODASÂ® (Spheroidal Oral Drug Absorption System) is Licensorâ€™s Multiparticulate drug delivery system. Based on the production of controlled release beads, the SODASÂ® technology is characterized by its inherent flexibility, enabling the production of customized dosage forms that respond directly to individual drug candidate needs.
Licensor is knowledgeable in the development of drug specific dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments,
IPSCIO Record ID: 166205
The SynchroMed system is the only externally programmable, implantable, drug infusion system available today. Using telemetry, the clinician can program its pump to deliver precise doses of medication at specific times to provide optimum therapy for each patient. It is widely used with morphine sulfate to block pain signals traveling to the brain and is also used to treat severe spasticity associated with multiple sclerosis, spinal cord injury, cerebral palsy, and traumatic brain injury. Clinical trials are expected to be initiated in 1998.